Subscribe for email alerts

Don’t miss a single Science & Enterprise post. Sign up for our daily email alerts.

Follow us on Twitter

  • Scientists Finish the Human Genome at Last https://t.co/bTRwmNjHwP
    about 9 hours ago
  • While the public's attention for the past 18 months has been focused on Covid-19, the problem of opioid overdoses a… https://t.co/gr0q6FkShP
    about 1 day ago
  • New post on Science and Enterprise: Infographic – Drug Overdose Epidemic Accelerating https://t.co/rZP0zmFVgK #Science #Business
    about 1 day ago
  • "Unvaccinated people aren’t a random group of defectors who are trying to be deviant." @edyong209 talks to Dr. Rhea… https://t.co/FkzZWK83OE
    about 1 day ago
  • U.S. drops cases against five researchers accused of hiding ties to Chinese military https://t.co/0D4YvwvjZq
    about 2 days ago

Please share Science & Enterprise

Scripps Institute, Sigma-Aldrich to Partner on Reagents

Beakers (Research.gov)

(Research.gov)

Scripps Research Institute in La Jolla, California is collaborating with Sigma-Aldrich Corp. in St. Louis to speed the availability of new chemical reagents for drug discovery to the scientific community. The deal calls for payments to Scripps from Sigma-Aldrich, a chemical and laboratory services company, although the size of the payments is not disclosed.

Under the agreement, Sigma-Aldrich will receive an exclusive license to commercialize new reagents developed in six labs at Scripps: Phil Baran, Carlos Barbas, Benjamin CravattPhillip DawsonBarry Sharpless, and Jin-Quan Yu. The research conducted in the labs covers various aspects of chemistry, biochemistry, and molecular biology.

Sigma-Aldrich will provide payments to Scripps for the research conducted in the labs that results in the discovery of new reagent compounds. The company will also assign a product number to each of the new reagents, and make them available to the research community on the same day as their publication in scientific journals.

Scripps and Sigma-Aldrich are already partnering on commercializing a collection of 10 zinc-based salts developed in the lab of Phil Baran. Scripps says one of the salts, a difluoromethylation reagent, is being used in large quantities by pharmaceutical companies for optimizing lead compounds.

In the past year, Scripps also established research collaborations with Janssen Pharmaceuticals and Bristol-Myers Squibb. This new deal is the first multi-lab partnership for Scripps with Sigma-Aldrich, or any other chemical supplier.

Read more:

*     *     *

Comments are closed.